Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial.
Saved in:
| Title: | Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial. |
|---|---|
| Authors: | Mercer LD; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA., Seña AC; University of North Carolina at Chapel Hill, Institute for Global Health and Infectious Diseases, Chapel Hill, NC, USA., Colgate ER; The Vaccine Testing Center, Department of Microbiology and Molecular Genetics, University of Vermont Larner College of Medicine, Burlington, VT, USA., Crothers JW; The Vaccine Testing Center, Department of Microbiology and Molecular Genetics, University of Vermont Larner College of Medicine, Burlington, VT, USA; Department of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine, Burlington, VT, USA., Wright PF; Geisel School of Medicine, Dartmouth, Hanover, NH, USA., Al-Ibrahim M; Pharmaron CPC, Baltimore, MD, USA., Tritama E; PT Bio Farma, Bandung, Indonesia., Vincent A; Polio and Picornavirus Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA., Mainou BA; Polio and Picornavirus Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA., Zhang Y; Polio and Picornavirus Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA., Konopka-Anstadt J; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA., Bandyopadhyay AS; Bill & Melinda Gates Foundation, Seattle, WA, USA., Fix A; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA., Konz JO; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA., Gast C; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA. Electronic address: cgast@path.org. |
| Source: | The Lancet. Infectious diseases [Lancet Infect Dis] 2025 Dec; Vol. 25 (12), pp. 1363-1376. Date of Electronic Publication: 2025 Aug 13. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40818478 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Mercer+LD%22">Mercer LD</searchLink>; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Seña+AC%22">Seña AC</searchLink>; University of North Carolina at Chapel Hill, Institute for Global Health and Infectious Diseases, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Colgate+ER%22">Colgate ER</searchLink>; The Vaccine Testing Center, Department of Microbiology and Molecular Genetics, University of Vermont Larner College of Medicine, Burlington, VT, USA.<br /><searchLink fieldCode="AU" term="%22Crothers+JW%22">Crothers JW</searchLink>; The Vaccine Testing Center, Department of Microbiology and Molecular Genetics, University of Vermont Larner College of Medicine, Burlington, VT, USA; Department of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine, Burlington, VT, USA.<br /><searchLink fieldCode="AU" term="%22Wright+PF%22">Wright PF</searchLink>; Geisel School of Medicine, Dartmouth, Hanover, NH, USA.<br /><searchLink fieldCode="AU" term="%22Al-Ibrahim+M%22">Al-Ibrahim M</searchLink>; Pharmaron CPC, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Tritama+E%22">Tritama E</searchLink>; PT Bio Farma, Bandung, Indonesia.<br /><searchLink fieldCode="AU" term="%22Vincent+A%22">Vincent A</searchLink>; Polio and Picornavirus Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Mainou+BA%22">Mainou BA</searchLink>; Polio and Picornavirus Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Polio and Picornavirus Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Konopka-Anstadt+J%22">Konopka-Anstadt J</searchLink>; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Bandyopadhyay+AS%22">Bandyopadhyay AS</searchLink>; Bill & Melinda Gates Foundation, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Fix+A%22">Fix A</searchLink>; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Konz+JO%22">Konz JO</searchLink>; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Gast+C%22">Gast C</searchLink>; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA. Electronic address: cgast@path.org. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101130150%22">The Lancet. Infectious diseases</searchLink> [Lancet Infect Dis] 2025 Dec; Vol. 25 (12), pp. 1363-1376. <i>Date of Electronic Publication: </i>2025 Aug 13. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101130150 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-4457 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214733099%22">14733099 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Infect Dis <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40818478 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S1473-3099(25)00285-3 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1363 Titles: – TitleFull: Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Mercer LD – PersonEntity: Name: NameFull: Seña AC – PersonEntity: Name: NameFull: Colgate ER – PersonEntity: Name: NameFull: Crothers JW – PersonEntity: Name: NameFull: Wright PF – PersonEntity: Name: NameFull: Al-Ibrahim M – PersonEntity: Name: NameFull: Tritama E – PersonEntity: Name: NameFull: Vincent A – PersonEntity: Name: NameFull: Mainou BA – PersonEntity: Name: NameFull: Zhang Y – PersonEntity: Name: NameFull: Konopka-Anstadt J – PersonEntity: Name: NameFull: Bandyopadhyay AS – PersonEntity: Name: NameFull: Fix A – PersonEntity: Name: NameFull: Konz JO – PersonEntity: Name: NameFull: Gast C IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: 2025 Dec Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1474-4457 Numbering: – Type: volume Value: 25 – Type: issue Value: 12 Titles: – TitleFull: The Lancet. Infectious diseases Type: main |
| ResultId | 1 |
